SCD-HeFT results published: more ICD (implantable cardioverter defibrillator) eligibility now in US?
This article was originally published in Clinica
The number of Medicare beneficiaries eligible to receive an implantable cardioverter defibrillator (ICD) as a primary prevention against sudden cardiac death (SCD) could more than double, now that the results of Medtronic's SCD-HeFT trial have finally appeared in a peer-reviewed medical journal.
You may also be interested in...
HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.